Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 18/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | TACR2 | P21452 | 13/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668628 | 0.85 | LMNA (0.49) | TACR3KCNH2TACR2LMNAOPRM1 | |
| SCHEMBL4665602 | 0.82 | LMNA (0.57) | TACR3TACR2LMNAOPRM1 | |
| SCHEMBL5045996 | 0.82 | LMNA (0.57) | TACR3TACR2LMNAOPRM1 | |
| SCHEMBL4665580 | 0.81 | LMNA (0.55) | TACR3TACR2LMNA | |
| SCHEMBL5042633 | 0.81 | LMNA (0.56) | TACR3TACR2LMNAOPRM1 | |
| SCHEMBL4667328 | 0.80 | LMNA (0.53) | TACR3TACR2LMNAOPRM1 | |
| SCHEMBL4668727 | 0.80 | LMNA (0.53) | TACR3TACR2LMNA | |
| SCHEMBL5042219 | 0.80 | LMNA (0.55) | TACR3TACR2LMNAOPRM1 | |
| SCHEMBL4667842 | 0.79 | TACR3 (0.56) | TACR3TACR2LMNA | |
| SCHEMBL5045776 | 0.79 | CYP2D6 (0.56) | TACR3TACR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940795-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007035156-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |